Studies on the Mechanism of Simvastatin-Induced Thyroid Hypertrophy and Follicular Cell Adenoma in the Rat
Authors:
Open Access
- 1 April 1991
- journal article
- research article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 19 (3) , 197-205
Abstract
Female Sprague-Dawley rats were treated with either simvastatin (a novel competitive inhibitor of HMG CoA reductase) or phcnobarbilal (positive control) to ascertain the possible relationship between the effects of simvastatin on hepatic metabolism and the thyroid hypertrophy and follicular cell adenomas which it produces in this strain of rat. The test compounds were administered orally at doses of 100 mg/kg (divided doses at 50 mg/kg, b.i.d.). (This dose of simvastatin represents approximately 250 times the human dose.) After 5 weeks of treatment, either simvastatin or phenobarbital produced significant increases (35% and 39% above control, respectively) in serum thyroid stimulating hormone (TSH), a significant increase (39% and 120% above control, respectively) in the systemic clearance of125I-thyroxine, and slight decreases in serum thyroxine levels. Statistically significant increases in liver and thyroid weights were associated with phenobarbital treatment. With simvastatin, increased liver weights occurred. At the microscopic level, thyroid hypertrophy was observed in all phenobarbital-treated rats and to a lesser degree in most simvastatin-treated animals. Simvastatin did not markedly alter liver microsomal enzyme activities with the exception of the anticipated induction of HMG CoA reductase (which increased approximately 4.4-fold). Conversely, phenobarbital produced large increases in liver microsomal enzymes, including glucuronosyl transferase, but did not affect the activity of HMG CoA reductase. Therefore, the increased clearance of thyroxine in simvastatin-treated female rats was not associated with enzyme induction but may have been related to the increase in functional liver mass produced by this compound at this dose. Finally, the thyroid change with simvastatin is likely to result from increased thyroxine clearance and the consequent stimulation of this gland from increased serum TSH.Keywords
This publication has 27 references indexed in Scilit:
- Effects of Purified Polybrominated Biphenyl Congeners on the Thyroid and Pituitary Glands in RatsJournal of the American College of Toxicology, 1992
- A simple method for the separation and quantitation of radiolabeled thyroid hormones in thyroxine clearance studiesJournal of Pharmacological Methods, 1990
- Preclinical evaluation of lovastatinThe American Journal of Cardiology, 1988
- Thyroid and liver trophic changes in rats secondary to liver microsomal enzyme induction caused by an experimental leukotriene antagonist (L-649,923)Toxicology and Applied Pharmacology, 1988
- Assessment of hyperplastic and neoplasfic lesions of the thyroid glandTrends in Pharmacological Sciences, 1987
- Changes in thyroidal function and liver UDPglucuronosyltransferase activity in rats following administration of a novel imidazole (SC-37211)Toxicology and Applied Pharmacology, 1985
- Lowering Plasma Cholesterol by Raising LDL ReceptorsNew England Journal of Medicine, 1981
- Determination of microsomal UDP-glucuronyltransferase in needle-biopsy specimens of human liverEuropean Journal of Clinical Pharmacology, 1978
- The Biliary Excretion of Thyroxine and Its GlucuronicAcid Conjugate in Normal and Gunn RatsEndocrinology, 1973
- A new method for measuring the free thyroid hormone in human serum and an analysis of the factors that influence its concentration.Journal of Clinical Investigation, 1965